RXST LAWSUIT: RxSight, Inc. Sued for Fraud after LDD Sales Plummet – Contact BFA Law by September 22 Court Deadline (NASDAQ:RXST)

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, specifically related to undisclosed challenges in product adoption and subsequent revenue forecast cuts [1][2][4]. Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Financial Performance and Stock Impact - The company experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors during a period when RxSight promoted strong sales [4]. - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - Following a further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell again by about 38%, from $12.79 to $7.95 per share [6].